Keywords
How to Cite
Abstract
Aim: to study the role of combined positron emission and computed tomography (PET/CT) with 11C-methionine in the diagnosis of patients with different types of lymphoma.
Material and methods. Uptake of 11C-methionine and 18F-FDG was studied with PeT/CT in 24 patients with histologically verified lymphoma. All patients underwent studies with both radiopharmaceuticals. A total of 48 studies were performed.
Results. All 24 patients had abnormal sites of pathological uptake of 11C-methionine and 18F-FDG. Regions of abnormal sites of metabolic activity were coinciding in examinations with both radiopharmaceuticals. The average uptake rate of 18F-FDG and 11C-methionine were 9,45 ± 1,3 and 6,7 ± 0,4, (p = 0,05) respectively. In patients with Hodgkin's lymphoma (HL) and aggressive non-Hodgkin's lymphoma (NHL) in comparison with indolent NHL patients the metabolic activity of the pathological focuses in examinations with both radiopharmaceuticals had a significant difference in the accumulation rate, depending on the degree of malignancy-p = 0,01 and p = 0,001, respectively. The sensitivity and specificity of PET/CT with 11C-methionine was 94,4% and 83,3%, respectively. The threshold value of SUVmax > 5,6 (p <0,0001), allows to differentiate lymphomas according to the degree of malignancy.
Conclusion. Most sites of tumor involvement in patients with HL and NHL well visualized using 11C-metnionine PET/ CT. All tumor sites had a different level of metabolic activity, higher in patients with aggressive NHL and HL. However it's utility in the abdomen is limited by uptake in normal structures.
References
Cerci J.J., Trindade E., Buccheri V. et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with hodgkin lymphoma across jurisdictions//Clinical Lymphoma, Myeloma and Leukemia. -2011. -Vol. 11 (4). -P. 314-320.
Cheson B.D. Role of functional imaging in the management of lymphoma//J. Clin. Oncol. -2011. -Vol. 29 (14). -P. 1844-1854.
Wood K.A., Hoskin P.J., Saunders M.I. Positron emission tomography in oncology: a review//Clin. Oncol. -2007. -Vol. 19 (4). -P. 237-255.
Zanoni L., Cerci J.J., Fanti S. Use of PET/CT to evaluate response to therapy in lymphoma//Quarterly Journal of Nuclear Medicine and Molecular Imaging. -2011. -Vol. 55 (6). -P. 633-647.
Basu S., Alavi A. Molecular imaging (PET) of brain tumors//Neuroimaging Clin. N. Amer. -2009. -Vol. 19 (4). -P. 625-646.
Leskinen-Kallio S., Ruotsalainen U., Nagren K. et al. Uptake of carbon 11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study//J. Nucl. Med. -1991. -Vol. 32 (6). -P. 1211-1218.
Nuutinen J., Leskinen S., Lindholm P., et al. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas//Eur. J. Nucl. Med. -1998. -Vol. 25 (7). -P. 729-735.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018